Literature DB >> 9152102

The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task.

R M Cohen1, T E Nordahl, W E Semple, P Andreason, R E Litman, D Pickar.   

Abstract

BACKGROUND: The comparison of the effects of 2 classes of neuroleptic drugs on regional brain functional activities may reveal common mechanisms of antipsychotic drug efficacy.
METHODS: The regional cerebral glucose metabolic rates of patients with schizophrenia who were and were not receiving neuroleptic drugs and normal control subjects were obtained by positron emission tomography using fludeoxyglucose F 18 as the tracer.
RESULTS: Compared with normal controls and patients not receiving medication, fluphenazine hydrochloride- and clozapine-treated patients had lower global gray matter absolute metabolic rates throughout the cortex. When normalized regional glucose metabolic rates were examined, both medications lowered rates in the superior prefrontal cortex and increased rates in the limbic cortex. Fluphenazine, but not clozapine, increased metabolic rates in the subcortical and lateral temporal lobes, whereas clozapine, but not fluphenazine, decreased inferior prefrontal cortex activity.
CONCLUSIONS: These changes are consistent with the idea that neuroleptic drugs lead to "compensation" and "adaptation" rather than "normalization" of the functional activities of brain structures in schizophrenia. The overall similarity of their global and regional metabolic effects suggests that both classes of antipsychotic drugs share some common mechanisms of action. One possibility is that of inducing a shift in the balance of cortical to limbic cortex activity. Differential effects in the inferior prefrontal cortex and the basal ganglia might underlie differences in the therapeutic efficacy and side effect profile of clozapine and fluphenazine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152102     DOI: 10.1001/archpsyc.1997.01830170107014

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  15 in total

1.  MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder.

Authors:  James J Levitt; Robert W McCarley; Chandlee C Dickey; Martina M Voglmaier; Margaret A Niznikiewicz; Larry J Seidman; Yoshio Hirayasu; Aleksandra A Ciszewski; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 2.  Predictors and markers of clozapine response.

Authors:  Carmen Chung; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

3.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

4.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

5.  Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.

Authors:  E T C Ngan; C J Lane; T J Ruth; P F Liddle
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

6.  Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder.

Authors:  James J Levitt; Carl Fredrik Westin; Paul G Nestor; Raul S J Estepar; Chandlee C Dickey; Martina M Voglmaier; Larry J Seidman; Ron Kikinis; Ferenc A Jolesz; Robert W McCarley; Martha E Shenton
Journal:  Biol Psychiatry       Date:  2004-01-15       Impact factor: 13.382

7.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

8.  Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia.

Authors:  Vicente Molina; Santiago Reig; Manuel Desco; Juan D. Gispert; Javier Sanz; Fernando Sarramea; Javier Pascau; Carlos Benito; Raul Martínez-Lázaro; Rogelio Luque; María Aragües; Jose M. Misiego; Ignacio López Corral; Thomás Palomo
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

9.  Reduction of caudate nucleus volumes in neuroleptic-naïve female subjects with schizotypal personality disorder.

Authors:  Min-Seong Koo; James J Levitt; Robert W McCarley; Larry J Seidman; Chandlee C Dickey; Margaret A Niznikiewicz; Martina M Voglmaier; Payman Zamani; Katherine R Long; Sunnie S Kim; Martha E Shenton
Journal:  Biol Psychiatry       Date:  2006-02-07       Impact factor: 13.382

10.  Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.

Authors:  Vicente Molina; Juan D Gispert; Santiago Reig; Javier Sanz; Javier Pascau; Andrés Santos; Manuel Desco; Tomás Palomo
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.